{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T19:02:12Z","timestamp":1768244532812,"version":"3.49.0"},"reference-count":88,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Qual"],"accepted":{"date-parts":[[2025,12,3]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Treatment of moderate to severe psoriasis typically requires the use of multiple systemic therapies over a patient\u2019s lifetime. The efficacy and safety of systemic treatments are typically evaluated in clinical trials; however, patient registries are increasingly used to monitor long-term outcomes of systemic therapies for psoriasis in real-world settings. Psoriasis registries also generate important real-world evidence about psoriasis treatment that may facilitate a greater understanding of outcomes outside of a controlled clinical trial setting. This study thus characterises the design and measures used in real-world studies of psoriasis treatment from patient registries and assesses its use in informing clinical guidelines and reimbursement decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A systematic literature review was conducted to identify real-world observational studies that used psoriasis registry data. PubMed and Embase were searched for English-language studies published between January 2018 and January 2023. To assess how real-world studies, clinical guidelines, and reimbursement and coverage reports have informed practice, treatment, and reimbursement guidelines, a narrative review of recommendations was conducted. All results were screened by two independent reviewers (LP and TAS) using prespecified inclusion and exclusion criteria. Outcomes of interest were extracted into Excel, with all conflicts resolved through discussion\/consensus. Tables displayed outcomes and research topics first by year, then by registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42023402431<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjoq-2024-003291","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T15:31:17Z","timestamp":1768231877000},"page":"e003291","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Role of real-world evidence from patient registries for psoriasis in decision-making: a systematic review"],"prefix":"10.1136","volume":"15","author":[{"given":"Lauren","family":"Passero","sequence":"first","affiliation":[{"name":"University of North Carolina, Chapel Hill, North Carolina, USA"},{"name":"WorldWide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa A","family":"Simon","sequence":"additional","affiliation":[{"name":"WorldWide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey, USA"},{"name":"Physicians Research Center, LLC, Toms River, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichen","family":"Zhong","sequence":"additional","affiliation":[{"name":"WorldWide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Zhuo","sequence":"additional","affiliation":[{"name":"WorldWide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1626-1507","authenticated-orcid":false,"given":"Stefan","family":"Varga","sequence":"additional","affiliation":[{"name":"WorldWide Medical Immunology, Bristol Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April W","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Division of Dermatology, David Geffen School of Medicine, University of California, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"2026011207303079000_15.1.e003291.1","unstructured":"Michalek IM , Loring B , Malte S . Global report on psoriasis Switzerland. World Health Organization; 2016. Available: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/204417\/9789241565189_eng.pdf.psoriasis?sequence=1"},{"key":"2026011207303079000_15.1.e003291.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"2026011207303079000_15.1.e003291.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"2026011207303079000_15.1.e003291.4","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/jdv.13634","article-title":"Psoriasis registries worldwide: systematic overview on registry publications","volume":"30","author":"Eissing","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026011207303079000_15.1.e003291.5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaad.2023.02.059","article-title":"Variables associated with joint involvement and development of a prediction rule for arthritis in patients with psoriasis. An analysis of the Italian PsoReal database","volume":"89","author":"Heidemeyer","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026011207303079000_15.1.e003291.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.10.019"},{"key":"2026011207303079000_15.1.e003291.7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026011207303079000_15.1.e003291.8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jdin.2020.10.012","article-title":"Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis","volume":"2","author":"Graier","year":"2021","journal-title":"JAAD Int"},{"key":"2026011207303079000_15.1.e003291.9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s13555-022-00865-0","article-title":"Effectiveness of guselkumab therapy among patients with plaque psoriasis with baseline IGA score \u2265 2 in the CorEvitas Psoriasis Registry","volume":"13","author":"Armstrong","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026011207303079000_15.1.e003291.10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s13555-022-00879-8","article-title":"Real-world effectiveness of 9\u201312 months of guselkumab therapy among patients with moderate-to-severe plaque psoriasis in the CorEvitas Psoriasis Registry","volume":"13","author":"Armstrong","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026011207303079000_15.1.e003291.11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/ajd.13895","article-title":"Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21\u2010month analysis in Australian routine clinical practice (sustain study)","volume":"63","author":"Foley","year":"2022","journal-title":"Aust J Dermatology"},{"key":"2026011207303079000_15.1.e003291.12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00403-019-01945-6","article-title":"Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT)","volume":"311","author":"Drach","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"2026011207303079000_15.1.e003291.13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s13555-021-00556-2","article-title":"Risankizumab for the treatment of moderate-to-severe psoriasis: Real-Life multicenter experience from the Czech Republic","volume":"11","author":"Gkalpakiotis","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026011207303079000_15.1.e003291.14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s13555-022-00870-3","article-title":"Sustained effectiveness of secukinumab across different body regions in patients with moderate-to-severe plaque psoriasis from the PURE Registry","volume":"13","author":"Gooderham","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026011207303079000_15.1.e003291.15","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s13555-021-00499-8","article-title":"Real-world evidence from more than 1000 patients treated With adalimumab for moderate-to-Severe psoriasis in the Czech Republic","volume":"11","author":"Kojanova","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026011207303079000_15.1.e003291.16","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1080\/09546634.2020.1853023","article-title":"Disease response and patient-reported outcomes among initiators of ixekizumab","volume":"33","author":"Shahriari","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2026011207303079000_15.1.e003291.17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/09546634.2019.1603361","article-title":"US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry","volume":"31","author":"Strober","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"2026011207303079000_15.1.e003291.18","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1080\/09546634.2022.2116266","article-title":"Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting","volume":"33","author":"Strober","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2026011207303079000_15.1.e003291.19","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/jamadermatol.2019.1783","article-title":"Association of serum ustekinumab levels with clinical response in psoriasis","volume":"155","author":"Tsakok","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2026011207303079000_15.1.e003291.20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","article-title":"Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry","volume":"78","author":"Strober","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2026011207303079000_15.1.e003291.21","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14808","article-title":"Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry","volume":"34","author":"Lockshin","year":"2021","journal-title":"Dermatol Ther"},{"key":"2026011207303079000_15.1.e003291.22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13555-022-00843-6","article-title":"Outcomes of biologic use in Asian compared with non-Hispanic White adult psoriasis patients from the CorEvitas Psoriasis Registry","volume":"13","author":"Yu","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026011207303079000_15.1.e003291.23","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1080\/09546634.2022.2089329","article-title":"Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity","volume":"33","author":"Enos","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2026011207303079000_15.1.e003291.24","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2021.100025","article-title":"Psoriasis severity, comorbidities, and treatment response differ among geographic regions in the United States","volume":"1","author":"Enos","year":"2021","journal-title":"JID Innov"},{"key":"2026011207303079000_15.1.e003291.25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/24755303221131257","article-title":"Proportions of biologic discontinuation among psoriasis patients with metabolic comorbidities","volume":"8","author":"Enos","year":"2023","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"2026011207303079000_15.1.e003291.26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13555-020-00479-4","article-title":"Characteristics of patients with psoriasis treated with apremilast in the Corrona Psoriasis Registry","volume":"11","author":"Gottlieb","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026011207303079000_15.1.e003291.27","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1007\/s13555-022-00834-7","article-title":"Outcomes in ixekizumab patients following exposure to secukinumab and other biologics in the CorEvitas Psoriasis Registry","volume":"12","author":"Lockshin","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026011207303079000_15.1.e003291.28","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s13555-022-00740-y","article-title":"Utilization trends and impact of secukinumab treatment on clinical outcomes in biologic-naive patients with psoriasis in a US real-world setting","volume":"12","author":"Strober","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026011207303079000_15.1.e003291.29","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1080\/09546634.2019.1656797","article-title":"Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry","volume":"32","author":"Van Voorhees","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2026011207303079000_15.1.e003291.30","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/09546634.2020.1720586","article-title":"Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry","volume":"32","author":"Van Voorhees","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2026011207303079000_15.1.e003291.31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2217\/cer-2020-0113","article-title":"Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry","volume":"10","author":"Wu","year":"2021","journal-title":"J Comp Eff Res"},{"key":"2026011207303079000_15.1.e003291.32","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18981"},{"key":"2026011207303079000_15.1.e003291.33","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jid.2017.10.005","article-title":"Risk of serious infection in patients with psoriasis receiving biologic therapies: A prospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"138","author":"Yiu","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2026011207303079000_15.1.e003291.34","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2026011207303079000_15.1.e003291.35","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jid.2017.09.044","article-title":"Differential drug survival of second-line biologic therapies in patients with psoriasis: Observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"138","author":"Iskandar","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2026011207303079000_15.1.e003291.36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jamadermatol.2018.0183","article-title":"Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR","volume":"154","author":"Mason","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2026011207303079000_15.1.e003291.37","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/jdv.16018","article-title":"Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study","volume":"34","author":"Rungapiromnan","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026011207303079000_15.1.e003291.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.11.015"},{"key":"2026011207303079000_15.1.e003291.39","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/bjd.17036","article-title":"Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (badbir)","volume":"180","author":"Yiu","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026011207303079000_15.1.e003291.40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jamadermatol.2020.4202","article-title":"Randomized trial replication using observational data for comparative effectiveness of secukinumab and ustekinumab in psoriasis: A study from the British Association of Dermatologists Biologics and Immunomodulators Register","volume":"157","author":"Yiu","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026011207303079000_15.1.e003291.41","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1445193"},{"key":"2026011207303079000_15.1.e003291.42","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40264-021-01065-z","article-title":"Signal detection and methodological limitations in a real-world registry: Learnings from the evaluation of long-term safety analyses in PSOLAR","volume":"44","author":"Bissonnette","year":"2021","journal-title":"Drug Saf"},{"key":"2026011207303079000_15.1.e003291.43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamadermatol.2020.5595","article-title":"Pregnancy outcomes in women with moderate-to-severe psoriasis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"157","author":"Kimball","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026011207303079000_15.1.e003291.44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2020.08.032","article-title":"Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis","volume":"84","author":"Langley","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026011207303079000_15.1.e003291.45","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40257-018-0388-z","article-title":"Effect of age of onset of psoriasis on clinical outcomes with systemic treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"19","author":"Singh","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2026011207303079000_15.1.e003291.46","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-019-0094-3","article-title":"Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics","volume":"3","author":"Ritchlin","year":"2019","journal-title":"BMC Rheumatol"},{"key":"2026011207303079000_15.1.e003291.47","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2017.08.051","article-title":"Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"78","author":"Strober","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2026011207303079000_15.1.e003291.48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjd.16102","article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026011207303079000_15.1.e003291.49","doi-asserted-by":"crossref","first-page":"151979","DOI":"10.1016\/j.semarthrit.2022.151979","article-title":"Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries","volume":"53","author":"Egeberg","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2026011207303079000_15.1.e003291.50","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3722","article-title":"Response to biologics during the first six months of therapy in biologic-na\u00efve patients with psoriasis predicts risk of disease flares: A Danish nationwide study","volume":"101","author":"Loft","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2026011207303079000_15.1.e003291.51","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2021.0221","article-title":"Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis","volume":"157","author":"Loft","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026011207303079000_15.1.e003291.52","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/jdv.18126","article-title":"Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study","volume":"36","author":"Loft","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026011207303079000_15.1.e003291.53","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v101.351","article-title":"Predictors of response to biologics in patients with moderate-to-severe psoriasis: A Danish nationwide cohort study","volume":"101","author":"Schwarz","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2026011207303079000_15.1.e003291.54","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/1346-8138.14834","article-title":"Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry","volume":"46","author":"Bayaraa","year":"2019","journal-title":"J Dermatol"},{"key":"2026011207303079000_15.1.e003291.55","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s13555-021-00616-7","article-title":"Drug persistence of biologic treatments in psoriasis: A Swedish national population study","volume":"11","author":"Schmitt-Egenolf","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026011207303079000_15.1.e003291.56","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/jdv.14583","article-title":"Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries","volume":"32","author":"Busard","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026011207303079000_15.1.e003291.57","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ad.2018.04.004","article-title":"Description of patients treated with biologic drugs as first-line systemic therapy in the BIOBADADERM Registry between 2008 and 2016","volume":"109","author":"Carretero Hern\u00e1ndez","year":"2018","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"2026011207303079000_15.1.e003291.58","doi-asserted-by":"crossref","first-page":"36","DOI":"10.23736\/S2784-8671.18.06032-7","article-title":"Use of fumaric acid derivatives in Italian reference centers for psoriasis","volume":"156","author":"Damiani","year":"2021","journal-title":"Ital J Dermatol Venereol"},{"key":"2026011207303079000_15.1.e003291.59","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1111\/ajd.13450","article-title":"Treatment modalities and risk of adverse events associated with biologic therapy: A 10\u2010year observational review of the Australasian Psoriasis Registry","volume":"62","author":"Doolan","year":"2021","journal-title":"Aust J Dermatology"},{"key":"2026011207303079000_15.1.e003291.60","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14944","article-title":"Investigation of prevalence of biologic use and discontinuation rates in moderate\u2010to\u2010severe psoriasis patients in Newfoundland and Labrador using real\u2010world data","volume":"34","author":"Gulliver","year":"2021","journal-title":"Dermatol Ther"},{"key":"2026011207303079000_15.1.e003291.61","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/bjd.19701","article-title":"Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis","volume":"184","author":"Graier","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026011207303079000_15.1.e003291.62","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-18790-9","article-title":"Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)","volume":"12","author":"Graier","year":"2022","journal-title":"Sci Rep"},{"key":"2026011207303079000_15.1.e003291.63","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/ijd.14429","article-title":"Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis","volume":"58","author":"Lunder","year":"2019","journal-title":"Int J Dermatol"},{"key":"2026011207303079000_15.1.e003291.64","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1080\/09546634.2022.2082354","article-title":"Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry","volume":"33","author":"Kojanova","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2026011207303079000_15.1.e003291.65","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biologicals.2018.04.003","article-title":"Drug survival of biologic therapies for the treatment of psoriasis: Results of Slovenian national registry","volume":"54","author":"Lunder","year":"2018","journal-title":"Biologicals"},{"key":"2026011207303079000_15.1.e003291.66","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/09546634.2018.1468064","article-title":"A retrospective observational study on biological drug treatment in a daily practice serving patients with psoriasis in Japan","volume":"30","author":"Ohata","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"2026011207303079000_15.1.e003291.67","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15772","article-title":"Efficacy of switches within the class of IL-17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological\/targeted therapy (BIOREP)","volume":"35","author":"Tichy","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026011207303079000_15.1.e003291.68","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/jdv.15978","article-title":"Real\u2010world comparative effectiveness of adalimumab, etanercept and methotrexate: a Swedish register analysis","volume":"34","author":"Svedbom","year":"2020","journal-title":"Acad Dermatol Venereol"},{"key":"2026011207303079000_15.1.e003291.69","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40266-022-00961-y","article-title":"Drug survival, safety, and effectiveness of biologics in older patients with psoriasis: A comparison with younger patients-A BioCAPTURE Registry study","volume":"39","author":"Ter Haar","year":"2022","journal-title":"Drugs Aging"},{"key":"2026011207303079000_15.1.e003291.70","first-page":"58","article-title":"Survival of biological therapeutics in psoriasis: retrospective analysis of 3-years data in a Turkish registry, PSORTAKSIS","volume":"52","author":"\u00d6zyurt","year":"2022","journal-title":"Turk J Med Sci"},{"key":"2026011207303079000_15.1.e003291.71","doi-asserted-by":"crossref","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials","volume":"64 Suppl 2","author":"Feldman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2026011207303079000_15.1.e003291.72","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.jaad.2019.01.039","article-title":"Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States","volume":"80","author":"Feldman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2026011207303079000_15.1.e003291.73","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.03.033","article-title":"Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry","volume":"83","author":"Daud\u00e9n","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026011207303079000_15.1.e003291.74","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1080\/09546634.2021.1922572","article-title":"The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry","volume":"33","author":"Munera-Campos","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2026011207303079000_15.1.e003291.75","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/jdv.14684","article-title":"The journey of adult psoriasis patients towards biologics: past and present - Results from the BioCAPTURE registry","volume":"32","author":"van den Reek","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026011207303079000_15.1.e003291.76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/4371471","article-title":"Epidemiology and clinical features of adult patients with psoriasis in Malaysia: 10-Year review from the Malaysian Psoriasis Registry (2007\u20132016)","volume":"2018","author":"Mohd Affandi","year":"2018","journal-title":"Dermatol Res Pract"},{"key":"2026011207303079000_15.1.e003291.77","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/1756-185X.14492","article-title":"Clinical characteristics, management, and quality of life of psoriasis patients with coexistent lupus erythematosus: Data from the Malaysian Psoriasis Registry","volume":"26","author":"Gan","year":"2023","journal-title":"Int J of Rheum Dis"},{"key":"2026011207303079000_15.1.e003291.78","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2340\/00015555-3221","article-title":"Smoking does not alter the therapy response to systemic anti-psoriatic therapies: A two-country, multi-centre, prospective, non-interventional study","volume":"99","author":"Anzengruber","year":"2019","journal-title":"Acta Derm Venerol"},{"key":"2026011207303079000_15.1.e003291.79","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/bjd.20387","article-title":"Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study","volume":"185","author":"Maul","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026011207303079000_15.1.e003291.80","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1684\/ejd.2020.3709","article-title":"Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care","volume":"30","author":"Mrowietz","year":"2020","journal-title":"Eur J Dermatol"},{"key":"2026011207303079000_15.1.e003291.81","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1080\/09546634.2022.2115285","article-title":"Response to fumaric acid esters for plaque type psoriasis in real-world practice is largely independent of patient characteristics at baseline - a multivariable regression analysis from the German Psoriasis Registry PsoBest","volume":"33","author":"Reich","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2026011207303079000_15.1.e003291.82","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjd.15757","article-title":"Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol\u20105D response of biological treatment in psoriasis: 10 years of real\u2010world data in the Swedish National Psoriasis Register","volume":"178","author":"Hjalte","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026011207303079000_15.1.e003291.83","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000528007","article-title":"The use of IL-17 and IL-23 inhibitors in Swedish clinical practice: A register-based analysis","volume":"239","author":"Norlin","year":"2023","journal-title":"Dermatology"},{"key":"2026011207303079000_15.1.e003291.84","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s13555-022-00849-0","article-title":"Effectiveness and safety of secukinumab in Latin American patients with moderate to severe plaque psoriasis: PURE Registry 12-month data","volume":"13","author":"Papp","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026011207303079000_15.1.e003291.85","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2147\/DDDT.S304168","article-title":"Incidence and risk factors of hepatic fibrosis in psoriatic patients receiving methotrexate with concomitant acitretin therapy and methotrexate monotherapy","volume":"15","author":"Rattanakaemakorn","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"2026011207303079000_15.1.e003291.86","article-title":"Methotrexate use for patients with psoriasis and risk of cutaneous squamous cell carcinoma: A nested case-control study","volume":"101","author":"Giannopoulos","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2026011207303079000_15.1.e003291.87","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjd.18887","article-title":"Methotrexate treatment for patients with psoriasis and risk of cutaneous melanoma: a nested case\u2013control study","volume":"183","author":"Polesie","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026011207303079000_15.1.e003291.88","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/pds.5132","article-title":"Risk of common infections among individuals with psoriasis in Sweden: A nationwide cohort study comparing secukinumab to ustekinumab","volume":"29","author":"Srinivas","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["BMJ Open Quality"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjoq-2024-003291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T15:31:33Z","timestamp":1768231893000},"score":1,"resource":{"primary":{"URL":"https:\/\/qir.bmj.com\/lookup\/doi\/10.1136\/bmjoq-2024-003291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,12]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjoq-2024-003291"],"URL":"https:\/\/doi.org\/10.1136\/bmjoq-2024-003291","relation":{},"ISSN":["2399-6641"],"issn-type":[{"value":"2399-6641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}